Skip to main content

Thank you Max! I agree, I am also looking forward to following the advancement of data-driven methodologies in the future. Considering that AML is often diagnosed in older individuals due to the accumulation of mutations over time, it is promising to know that data-driven methodologies have progressed enough to help determine the best treatment approach for paediatric patients (4). However, due to the diversity in genetic and clinical profiles of AML patients, these databases might not contain data for each unique variation of the disease that a patient may present with. Without this data, it may be difficult for physicians to determine the best treatment approach for their patients. I wonder whether this will be a limitation to the use of databases in AML treatment?

Name
Melinda Chelva

Plain text

  • No HTML tags allowed.
  • Lines and paragraphs break automatically.
  • Web page addresses and email addresses turn into links automatically.